Evidence of house dust mite immunotherapy in paediatric asthma: a review
Exploration of Asthma & Allergy · 2025
DOI: 10.37349/eaa.2025.100979 ↗Kurz gefasst
Fachartikel in der Zeitschrift Exploration of Asthma & Allergy, 2025. Verfasst von Melvin Lee Qiyu. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Asthma is a prevalent chronic respiratory condition in children, often exacerbated by allergic reactions, with house dust mites (HDMs) being a significant trigger. Traditional asthma management primarily involves inhaled corticosteroids and bronchodilators, which do not address the underlying allergic mechanisms. Allergen immunotherapy, including subcutaneous and sublingual immunotherapy (SLIT), has emerged as a strategy to induce immune tolerance to allergens. This review evaluates the efficacy of HDM immunotherapy in paediatric asthma, focusing on reductions in asthma exacerbations, improvements in lung function, decreases in medication use, and enhancements in quality of life (QoL). The review highlights that both subcutaneous immunotherapy (SCIT) and SLIT significantly reduce asthma exacerbations in children, with SCIT showing superior efficacy in lung function improvement. Combination therapies, particularly SCIT with biologics, demonstrate enhanced outcomes, including exacerbations and medication use reductions. SCIT has also been shown to improve lung function more effectively than SLIT, particularly in children with high baseline levels of HDM-specific IgE. In terms of safety, both SCIT and SLIT are generally well-tolerated, though SCIT is associated with more localized and systemic reactions, which can be mitigated by combination with biologics. Furthermore, HDM immunotherapy significantly enhances the QoL in paediatric patients by reducing asthma symptoms and improving sleep, leading to long-lasting benefits. Despite these positive outcomes, there remain gaps in knowledge, particularly regarding the optimal duration of therapy and long-term effects post-treatment. Future research should standardize treatment protocols, explore personalized approaches, and investigate the long-term sustainability of treatment benefits to fully optimize the use of HDM immunotherapy in paediatric asthma.
Zitieren
APA
Qiyu, M. L. (2025). Evidence of house dust mite immunotherapy in paediatric asthma: a review. Exploration of Asthma & Allergy. https://doi.org/10.37349/eaa.2025.100979
Vancouver
Qiyu ML. Evidence of house dust mite immunotherapy in paediatric asthma: a review. Exploration of Asthma & Allergy. 2025. doi:10.37349/eaa.2025.100979
BibTeX
@article{Qiyu2025,
author = {Qiyu, Melvin Lee},
title = {Evidence of house dust mite immunotherapy in paediatric asthma: a review},
journal = {Exploration of Asthma & Allergy},
year = {2025},
doi = {10.37349/eaa.2025.100979}
}
EUVIMED